

**Congress of the United States**  
**House of Representatives**

COMMITTEE ON OVERSIGHT AND ACCOUNTABILITY

2157 RAYBURN HOUSE OFFICE BUILDING

WASHINGTON, DC 20515-6143

MAJORITY (202) 225-5074  
MINORITY (202) 225-5051

<https://oversight.house.gov>

July 5, 2023

Dr. Judith A. McMeekin  
Associate Commissioner for Regulatory Affairs  
U.S. Food and Drug Administration  
10903 New Hampshire Ave.  
Silver Spring, MD 20993

Dear Dr. McMeekin:

The Committee on Oversight and Accountability Subcommittee on Health Care and Financial Services is continuing to investigate the U.S. Food and Drug Administration's (FDA) response to the 2022 infant formula shortage. Based on our investigation, the Subcommittee believes you have valuable information that will inform its understanding of the FDA's response to this crisis. We therefore request that you make yourself available for a transcribed interview.

To schedule the transcribed interview or ask any related follow-up questions, please contact the Committee on Oversight and Accountability Majority Staff at (202) 225-5074 no later than July 12, 2023.

The Committee on Oversight and Accountability is the principal oversight committee of the U.S. House of Representatives and has broad authority to investigate "any matter" at "any time" under House Rule X.

Sincerely,



Lisa McClain

Chairwoman

Subcommittee on Health Care and Financial Services

cc: The Honorable Katie Porter, Ranking Member  
Subcommittee on Health Care and Financial Services